![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
The cyclophilin inhibitor CRV431 prevents both HBx-cyclophilin complex formation and HBV replication
|
|
|
Reported by Jules Levin
EASL 2017 April 19-23 Amsterdam Netherlands
R. FOSTER1, D. URE1, D. TREPANIER1, P. GALLAY2
1 Contravir Pharmaceuticals Inc, Edison, New Jersey, USA and Edmonton, Alberta, Canada
2 The Scripps Research Institute, La Jolla, California, USA
![0505171](../images/050517/050517-6/0505171.gif)
![0505172](../images/050517/050517-6/0505172.gif)
![0505173](../images/050517/050517-6/0505173.gif)
![0505174](../images/050517/050517-6/0505174.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|